| [2010/07/02] |
NIHON KEIZAI SHIMBUN published an article titled “ iPS cells from a tiny drop of blood” reporting that Dr. Keiichi Fukuda, Professor of Keio University School of Medicine, successfully generated iPS cells from a very small amount of blood utilizing DNAVEC’s Sendai virus as a gene transfer vehicle. The work has been published in “Cell Stem Cell” on-line magazine. |
| [2010/06/28] |
International AIDS Vaccine Initiative (IAVI) announced that the organization will receive a total amount of US$10 million from Japanese government for the next 5 years to support the development of an AIDS vaccine based on Sendai virus vector. |
| [2010/06/28] |
METI-Kanto (Kanto Bureau of Economy, Trade and Industry)’s on line magazine “ Itto Jukken” published an article titled “ iPS cell preparation vector kit to hit the market, based on an original vector technology,” that introduced DNAVEC’s CytoTune™-iPS kit. |
| [2010/06/16] |
NIHON KEIZAI SHINBUN in an article titled “DNAVEC ready to sell iPS cell preparing kit; no damage to genes,” and NIKKEI SANGYO SHINBUN in an article titled "iPS cell preparation vector kit; 250,000 yen per kit; DNAVEC, high safety" reported that DNAVEC had started selling an iPS cell preparation vector kit – CytoTuneTM-iPS as a research reagent intended for research laboratories and institutions in Japan. |
| [2010/06/15] |
DNAVEC launched the iPS cell preparation Senai virus vector kit CytoTune™-iPS. |
| [2010/03/18] |
Company’s headquarters & laboratories moved and consolidated in Techno Park Oho. |
| [2010/01/06] |
YOMIURI SHIMBUN reported in an article titled “Sendai virus, which was discovered by former president of Tohoku University Ishida who passed away last month, becomes a useful tool for iPS cell preparation" that DNAVEC is about to launch a new iPS cell preparation kit that is intended for research laboratories and utilizes DNAVEC’s vector technologies built on Sendai virus discovered by the late Dr. Ishida. |
| [2009/11/25] |
NIKKEI SANGYO SHINBUN reported in an article titled "iPS cells; ways to prevent cancerous transformation" that DNAVEC developed vector technologies for iPS cell preparation that allow generation of iPS cells without causing damage to the chromosomes of human somatic cells, and that the company is ready to sell the vectors to research laboratories and institutions starting from as early as December. The article also reported the Harvard University Study focusing on the balance of gene expression during the process of iPS cells turning cancerous and the technology developed by Otsuka Pharmaceutical Co., Ltd. that allows prediction of cancerous transformation of iPS cells by use of luminescence gene. |
| [2009/10/08] |
NIHON KEIZAI SHIMBUN reported in an article titled “Release of iPS cell preparation kit” that DNAVEC will initiate sales of a recombinant vector kit for iPS cell generation. |
| [2009/10/06] |
MAINICHI SHIMBUN reported in an article titled “iPS cell production, greater safety achieved” that mentioned DNAVEC’s new technology for the generation of iPS cells. |
| [2009/09/30] |
ASAHI SHIMBUN published an article titled “Reducing the risk of creating tumors, an efficient iPS induction method”, NIKKEI SANGYO SHIMBUN also published an article titled “DNAVEC, generation of iPS cells with greater safety by Sendai virus,” on DNAVEC’s new technology for iPS cell generation. |
| [2009/09/30] |
NIKKEI BUSINESS PUBLICATIONS, Inc. presented a detailed description of DNAVEC’s iPS cell generation technology in an online article titled “Using Sendai virus, DNAVEC develops a technology to generate iPS cells with no chromosomal insertions, opens a path to standardization and applications in regenerative medicine, takes the safety issues of iPS cells onto a second stage.” |
| [2009/04/13] |
WEEKLY DIAMONDD (Issue of April 18, 2009) published a special article entitled “Nippon’s invention power” that reported DNAVEC was selected as one of the seven biotech companies among the “50 venture companies chosen by the connosseurs”. |
| [2009/04/09] |
NIHON KEIZAI SHIMBUN and NIKKEI SANGYO SHIMBUN reported DNAVEC’s alliance with West China Medical School West China Hospital of Sichuan University (Chengdu, Sichuan prefecture, P.R.China) in the development of gene therapeutics for glaucoma. |
| [2009/03/17] |
NIKKEI BIOTECH reported in an article titled “ Kyushu University presents a progress report on the gene therapy for critical limb ischemia using Sendai virus vector” that nine out of 15 patients enrolled by the end of January 2009 have been administered with Sendai virus vector carrying human fibroblast growth factor 2 gene (SeV/dF-FGF2) in the clinical research currently underway at Kyushu University. Amelioration of rest pain was observed in all six patients who received the drug at therapeutic doses where some degree of efficacy was anticipated. |
| [2008/09/12] |
NIKKEI SANGYO SHIMBUN reported that DNAVEC had launched collaboration with Keiichi Fukuda, Professor of School of Medicine of Keio University in the development of gene therapy for intractable Pulmonary Arterial Hypertension (PAH). |
| [2008/08/06] |
ASAHI SHIMBUN reported an interview with Richard Feachem, Executive Director of Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), expressed in his expectations of ongoing collaboration in the development of AIDS vaccine between DNAVEC and the International AIDS Vaccine Initiative (IAVI), the world largest NGO of the kind. |
| [2008/05/30] |
NIKKAN KOGYO SHIMBUN reported that DNAVEC had reached an agreement with National Vaccine & Serum Institute of China in the development of Herpes vaccine. |
| [2008/04/03] |
NIKKEI SANGYO SHIMBUN reported in an article titled “Japanese venture DNAVEC will develop avian flu vaccine using gene vector in collaboration with Chinese Academy of Science” that DNAVEC and Chinese Academy of Sciences Institute of Microbiology reached an agreement on the collaborative development of Avian Influenza vaccine. |
| [2008/01/31] |
Updated “Job Opportunities,” announcing positions available for researchers and research technicians. |
| [2008/01/31] |
Renewed the Japanese home page. |
| [2007/11/05] |
NIHON KEIZAI SHIMBUN reported an interview with Seth F. Berkley, President and CEO of International AIDS Vaccine Initiative (IAVI), titled “Bringing a Japanese mucosal AIDS vaccine to clinical trials.” IAVI is one of our partners in the development of AIDS vaccines. |
| [2007/10/16] |
Received the Japan Bioindustry Association Award of the Japan Bio-venture Awards. |
| [2007/10/09] |
NIKKEI SANGYO SHIMBUN published an article on the clinical development of DNAVEC’s AIDS vaccine in the United States. |
| [2007/08/12] |
NIHON KEIZAI SHIMBUN published a SCIENCE section article titled “Realizing AIDS Eradication” on DNAVEC’s collaboration with the University of Tokyo and the National Institute of Infectious Diseases of Japan in the development of AIDS vaccines. |
| [2007/07/07] |
YOMIURI SHIMBUN reported DNAVEC’s alliance with the International AIDS Vaccine Initiative (IAVI), the largest organization of this kind and supported by donations from charity organizations such as Bill and Melinda Gates Foundation, in the development of a Japan-made AIDS vaccine. |
| [2007/05/25] |
NIKKAN KOGYO SHIMBUN reported that DNAVEC agreed to transfer technologies to SiBiono GeneTech Co.,Ltd. (Shenzhen, Guangdong prefecture P.R.China) for the development of world’s first anti-AIDS virus (HIV) gene therapy. |
| [2007/02/26] |
NIKKEI SANGYO SHIMBUN reported in a special section devoted to Eisai’s anti-Alzheimer’s disease drugs, DNAVEC-Eisai alliance in the development of a gene vaccine for Alzheimer’s disease using amyloid β gene. |
| [2006/11/29] |
JOYO SHIMBUN carried “Frontiers in Gene Therapy Part 2”. |
| [2006/11/22] |
JOYO SHIMBUN carried part one of the two-part interview with Dr. Mamoru Hasegawa, President and CEO of DNAVEC, titled ”Frontiers in Gene Therapy Part 1” as a part of the interview series “The Life of Presidents, 100 Venture Companies in Tsukuba.” In the interview, Dr. Hasegawa talked about the history and ongoing business of DNAVEC. |
| [2006/10/28] |
NIHON KEIZAI SHIMBUN(THE NIKKEI), JOYO SHIMBUN and IBARAKI SHIMBUN reported that DNAVEC was the recipient of the Second Tsukuba Venture Award, which recognizes venture companies that developed innovative and excellent technologies and business models. |
| [2006/08/28] |
NIKKEI BIOTECH reported the custom-made antibody preparation service of Medical & Biological Laboratories Co., Ltd., which utilizes DNAVEC’s Sendai virus vector technologies. |
| [2006/07/25] |
NIKKEI SANGYO SHIMBUN reported DNAVEC-Eisai alliance in the development of a gene vaccine for Alzheimer’s disease using amyloid β gene. |
